Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2008

01-07-2008 | Original Article

Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results

Authors: Laura L. Travaini, Giuseppe Trifirò, Laura Ravasi, Lorenzo Monfardini, Paolo Della Vigna, Guido Bonomo, Antonio Chiappa, Andrew Mallia, Mahila Ferrari, Franco Orsi, Giovanni Paganelli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2008

Login to get access

Abstract

Purpose

Focal metastasis may be treated with radiofrequency ablation (RFA), a low invasive method yet limited by the lack of direct evidence of radicality of treatment. We, hereby, aimed at assessing the role of positron emission tomography–computed tomography (PET/CT) with fluoride radiolabeled deoxy-glucose ([18F]FDG) in RFA treatment success evaluation and early diagnosis of local relapse of liver metastasis after RFA procedure.

Methods

RFA was performed in nine patients on 12 liver metastasis, serially imaged through [18F]FDG-PET/CT and multidetector CT (MDCT) at 1, 3, 6, and 9 months after treatment. Eight lesions were also scanned with [18F]FDG-PET/CT at 1 week after treatment. Imaging analyses were performed on 47 [18F]FDG-PET/CT and 51 MDCT. Imaging reading outcomes were compared to each other and to biopsy tissue results when available.

Results

In one case, [18F]FDG-PET/CT revealed radiotracer uptake at RFA site a week after procedure. Negative concordant outcome was obtained on eight lesions at 1 month after RFA, on eight cases at 3 months, on four at 6 months, and on two cases at 9 months. Extra-liver (peritoneal) disease was detected in one case by both [18F]FDG-PET/CT and MDCT. In seven cases, [18F]FDG-PET/CT revealed the presence of local recurrence earlier than MDCT. In no cases did MDCT detect local relapse earlier than [18F]FDG-PET/CT.

Conclusion

[18F]FDG-PET/CT may detect RFA treatment failure as well as local relapse after RFA earlier than MDCT.
Literature
1.
Wilson SM, Adson Ma. Surgical treatment of hepatic metastases from colorectal cancer. Arch Surg. 1976;111:330–4.PubMed
2.
Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef
3.
Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut. 2002;50:1–5.PubMedCrossRef
4.
Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743–51.PubMedCrossRef
5.
Ravikumar TS, Steele G, Kane R, King V. Experimental and clinical observations on hepatic surgery for colorectal cancer. Cancer Res. 1991;51:6323–7.PubMed
6.
Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology. 2001;48:333–7.PubMed
7.
Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 2000;7:593–600.PubMed
8.
Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound. 2001;13:149–58.PubMedCrossRef
9.
Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293–9.PubMedCrossRef
10.
Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388–95.PubMedCrossRef
11.
Wiering B, Ruers TJ, Oven WJ. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Expert Rev Anticancer Ther. 2004;4:607–13.PubMedCrossRef
12.
Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784–8.PubMed
13.
Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30:286–91.PubMedCrossRef
14.
Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carried-added 2-[18F]-fluoro-2-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.PubMed
15.
Kamel E, Hany TF, Burger C, Treyer V, Lonn AH, von Schulthess GK, et al. CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging. 2002;29:346–50.PubMedCrossRef
16.
Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348–60.PubMedCrossRef
17.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15–3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27:1963–8.PubMed
18.
Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. Nucl Med. 2005;46:520–5.
19.
Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–7.PubMedCrossRef
20.
Anderson GS, Brinkman F, Soulen MC, Alavi A, Zhuang H. FDG Positron Emission Tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nuc Med. 2003;28:192–7.CrossRef
21.
Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, et al. [F-18] Fluorodeoxyglucose Positron Emission Tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. Journal Surg Onc. 2003;84:215–23.CrossRef
22.
Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027–35.PubMedCrossRef
23.
Takahashi S, Kuroki Y, Nasu K, Nawano S, Konishi M, Nakagohri T, et al. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res. 2006;26:4705–11.PubMed
24.
Zanotti-Fregonara P, Hindié E, Albertini AF, Ech-Charraq I, Weinmann P, Devaux JY. FDG (18)F-FDG PET/CT visualisation of tumor seeding after percutaneous radiofrequency ablation of metastases. Eur J Nucl Med Mol Imaging. 2007;34:305.PubMedCrossRef
Metadata
Title
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results
Authors
Laura L. Travaini
Giuseppe Trifirò
Laura Ravasi
Lorenzo Monfardini
Paolo Della Vigna
Guido Bonomo
Antonio Chiappa
Andrew Mallia
Mahila Ferrari
Franco Orsi
Giovanni Paganelli
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0748-7

Other articles of this Issue 7/2008

European Journal of Nuclear Medicine and Molecular Imaging 7/2008 Go to the issue

Review Article

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

Original Article

Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation

Letter to the Editor

Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

Original Article

Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study

Original Article

The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI

Original Article

Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons